ABT’s ABSORB product is approved for marketing in 30 countries, but is still in phase-3 in the US (#msg-83166556). As the above article notes, ABT prefers to call its ABSORB product a scaffold rather than a stent, as the latter term suggests permanence.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”